April 28, 2026 Reacta Healthcare Announces Expansion into Asia-Pacific and Appoints Professor Gary Wing-Kin Wong to Advisory Board
April 28, 2026 Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer
